AOD 9604 vs Tesamorelin: How These Fat-Loss Peptides Compare

AOD 9604 and tesamorelin are both peptides studied for their effects on fat tissue, but they are not interchangeable. Tesamorelin is an FDA-approved growth hormone–releasing hormone (GHRH) analog used for a specific medical condition, while AOD 9604 is a research-only fragment of human growth hormone with no approved human use. The main difference is that tesamorelin works through the pituitary to raise growth hormone and IGF-1, and AOD 9604 is designed to act more directly on fat cells.

What Is AOD 9604?

AOD 9604 is a modified peptide fragment of human growth hormone, corresponding to amino acids 176–191 of the hGH molecule. Researchers developed it to isolate the fat-metabolizing part of hGH while avoiding effects on blood sugar and growth.

In laboratory and animal studies, AOD 9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat storage). It is sometimes described as an anti-obesity peptide, but that label oversells the evidence.

• Class: hGH fragment peptide (176–191)
• FDA status: Not approved for human use
• Typical research dose: 300–600 mcg per day, often split into two injections
• Common research focus: Fat loss, metabolic markers

Human data on AOD 9604 are limited. Some early trials explored it for obesity, but results were modest and the peptide never received regulatory approval. For a broader comparison, many readers also review aod 9604 peptide vs tesamorelin.

What Is Tesamorelin?

Tesamorelin is a synthetic GHRH analog. It binds to GHRH receptors in the pituitary gland and prompts the body to release its own growth hormone, which in turn raises IGF-1.

The FDA approved tesamorelin (brand name Egrifta) for HIV-associated lipodystrophy, specifically to reduce excess visceral abdominal fat in adults with the condition. It is not approved for general weight loss or cosmetic fat reduction.

• Class: GHRH analog
• FDA status: Approved for HIV-associated lipodystrophy
• Approved dose: 2 mg subcutaneous injection once daily
• Common side effects: Injection-site reactions, joint pain, muscle pain, swelling, carpal tunnel symptoms

Tesamorelin can raise IGF-1, and long-term elevation of IGF-1 is a theoretical concern that requires monitoring. People with active cancer, pituitary tumors, or pregnancy should not use tesamorelin.

AOD 9604 vs Tesamorelin: Key Differences

The two peptides differ in origin, mechanism, approval status, and risk profile. The table below summarizes the main points.

One important conclusion: AOD 9604 and tesamorelin are not direct substitutes because they work through different biological pathways.

Another key point: tesamorelin has human safety and efficacy data for a narrow medical indication, while AOD 9604 does not have that level of evidence.

Can You Use AOD 9604 and Tesamorelin Together?

People sometimes search for aod 9604 and tesamorelin together, hoping to combine direct fat-cell effects with increased growth hormone. The idea is theoretically appealing because the mechanisms are complementary.

However, there are no published human trials of this combination. Stacking them could amplify side effects such as joint pain, fluid retention, and IGF-1 elevation. Without clinical data, the risk-to-benefit ratio is unknown.

There is no published human trial data on combining AOD 9604 and tesamorelin, so any stack use is experimental and unmonitored.

If you are researching aod-9604 mots-c tesamorelin stack protocols, keep in mind that MOTS-c is another research peptide with its own unknowns, and adding more compounds increases uncertainty.

Anyone considering these peptides should consult a healthcare professional and use only FDA-approved medications when legally prescribed.

How They Compare to Other Fat-Loss and GH Peptides

The research peptide landscape is crowded. AOD 9604 is often compared with newer metabolic agents and GH secretagogues.

• aod 9604 vs mots-c: MOTS-c is a mitochondrial-derived peptide studied for insulin sensitivity and metabolic regulation, while AOD 9604 targets fat cells directly.
• aod 9604 vs retatrutide: Retatrutide is an investigational triple agonist (GLP-1/GIP/glucagon) with strong clinical trial weight-loss data, a completely different drug class from AOD 9604.
• aod-9604 vs cjc-1295 ipamorelin: CJC-1295 and ipamorelin are GH secretagogues that raise GH and IGF-1, similar in goal to tesamorelin but not FDA-approved for fat reduction.

These comparisons show that AOD 9604 sits in a different category from incretin-based drugs like retatrutide. It also differs from GH-releasing peptides, which affect the whole growth hormone axis.

Safety and Legal Considerations in the US

AOD 9604 is sold online as a research chemical, but it is not approved for human consumption. The FDA has warned that research peptides sold for human use may be misbranded or unsafe.

Tesamorelin is a prescription drug in the US and must be prescribed by a licensed healthcare provider. It requires monitoring of IGF-1 and prostate-specific antigen (PSA) in some patients, according to prescribing information.

Neither peptide is a cosmetic weight-loss cure. Diet, exercise, and medically supervised treatments remain the foundation for fat loss.

Before using any peptide, discuss risks, benefits, and alternatives with a qualified clinician.